While in Australia last month, Botanix CEO Dr Howie McKibbon spoke with Bell Direct’s Grady Wulff about the Company’s FDA-approved product, Sofdra™, the competitive landscape in dermatology, and the outlook for Botanix over the next 12 months.
Take a look:
Botanix CEO Howie McKibbon recently visited Australia to meet with investors, and to present at the ASX Small and Mid-Cap Conference and the E&P Small Cap Healthcare Conference.
During his visit, he was interviewed in the Ausbiz studio to discuss the Company’s comprehensive commercialisation plans for Sofdra™. Take a look:
Botanix provides a staffing update as it prepares for the planned launch of Sofdra™ (sofpironium) 12.45% in Q4 CY2024 and announces issuance of its Notice of Meeting for the Annual General Meeting on 4 November 2024 which was released to ASX today.
